472 related articles for article (PubMed ID: 30845156)
1. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
[TBL] [Abstract][Full Text] [Related]
2. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
[TBL] [Abstract][Full Text] [Related]
3. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
4. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
van den Belt SM; Heerspink HJL; Kirchner M; Gracchi V; Thurn-Valsassina D; Bayazit AK; Niemirska A; Canpolat N; Kaplan Bulut I; Azukaitis K; Duzova A; Bacchetta J; Shroff R; Paripovic D; Özçakar ZB; Fidan K; Erdogan H; Gellermann J; Wühl E; de Zeeuw D; Melk A; Querfeld U; Schaefer F
Clin J Am Soc Nephrol; 2020 May; 15(5):625-632. PubMed ID: 32253275
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
8. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
[TBL] [Abstract][Full Text] [Related]
9. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease.
Santoro A; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Degli Esposti L
J Nephrol; 2022 Mar; 35(2):463-472. PubMed ID: 34115311
[TBL] [Abstract][Full Text] [Related]
10. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
[TBL] [Abstract][Full Text] [Related]
11. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
[TBL] [Abstract][Full Text] [Related]
13. RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study.
Riccio E; Capuano I; Buonanno P; Andreucci M; Provenzano M; Amicone M; Rizzo M; Pisani A
Front Cardiovasc Med; 2022; 9():824095. PubMed ID: 35224054
[TBL] [Abstract][Full Text] [Related]
14. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
[TBL] [Abstract][Full Text] [Related]
15. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.
Evans M; Palaka E; Furuland H; Bennett H; Linde C; Qin L; McEwan P; Bakhai A
BMC Nephrol; 2019 Jan; 20(1):31. PubMed ID: 30704421
[TBL] [Abstract][Full Text] [Related]
16. Optimally managing hyperkalemia in patients with cardiorenal syndrome.
Wang AY
Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii36-iii44. PubMed ID: 31800079
[TBL] [Abstract][Full Text] [Related]
17. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
[TBL] [Abstract][Full Text] [Related]
18. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink.
Furuland H; McEwan P; Evans M; Linde C; Ayoubkhani D; Bakhai A; Palaka E; Bennett H; Qin L
BMC Nephrol; 2018 Aug; 19(1):211. PubMed ID: 30134846
[TBL] [Abstract][Full Text] [Related]
19. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
Mahmud HA; Palmer BF
Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
[TBL] [Abstract][Full Text] [Related]
20. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
